Back to Search Start Over

VioQuest doses first patient in trial of triciribine-phosphate as leukemia treatment

Source :
Science Letter. October 10, 2006, 884
Publication Year :
2006

Abstract

VioQuest Pharmaceuticals, Inc. (VQPH), a New Jersey-based biopharmaceutical company, announced that it has dosed the first patient in its phase 1/2a clinical trial of VQD-002, triciribine-phosphate (TCN-P) at the University [...]

Details

Language :
English
ISSN :
15389111
Database :
Gale General OneFile
Journal :
Science Letter
Publication Type :
News
Accession number :
edsgcl.246466323